Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
نویسندگان
چکیده
منابع مشابه
Medical Treatment of Cushings Disease: Somatostatin Analogues and Pasireotide
Cushing’s disease is Cushing’s syndrome caused by an adrenocorticotropic hormone-secreting pituitary adenoma and, in the absence of adequate treatment, can be fatal. Cushing’s disease represents an unmet medical need, with no approved medical therapies. Pasireotide is a novel multi-receptor-targeted somatostatin analogue with high affinity for sst 1,2,3 and sst 5 . Compared with octreotide, pas...
متن کاملMedical Treatment of Cushings Disease: Somatostatin Analogues and Pasireotide
Cushing’s disease is Cushing’s syndrome caused by an adrenocorticotropic hormone-secreting pituitary adenoma and, in the absence of adequate treatment, can be fatal. Cushing’s disease represents an unmet medical need, with no approved medical therapies. Pasireotide is a novel multi-receptor-targeted somatostatin analogue with high affinity for sst 1,2,3 and sst 5 . Compared with octreotide, pas...
متن کاملThe Efficacy of Silymarin and Vitamin E in Non-Alcoholic Fatty Liver Disease: A Clinical Trial
Abstract Objective: Nowadays, lifestyle modification is the best treatment recommended to patients with the nonalcoholic fatty liver disease (NAFLD). The therapeutic effects of vitamin E and silybin on liver functions were documented. The present study was conducted to examine the effect of silymarin and vitamin E on patients with NAFLD. Materials and Methods: From September 2014 to March 201...
متن کاملA 12-month phase 3 study of pasireotide in Cushing's disease.
BACKGROUND Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the ...
متن کاملEfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, non...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Diabetes & Endocrinology
سال: 2018
ISSN: 2213-8587
DOI: 10.1016/s2213-8587(17)30326-1